Literature DB >> 3754557

Studies on the mammary tumor-inhibiting effects of diethylstilbestrol and its mono- and diphosphate.

M R Schneider, E von Angerer, J Prekajac, W P Brade.   

Abstract

Diethylstilbestrol (DES), diethylstilbestrol monophosphate (DES-MP) and diethylstilbestrol diphosphate (DES-DP) were tested for their estrogen receptor affinity, estrogenic potency and mammary tumor-inhibiting activity in vitro and in vivo. DES had a much higher receptor binding affinity than its mono- or diphosphate. All three compounds inhibited the growth of the hormone-dependent MCF-7 and hormone-independent MDA-MB 231 breast cancer line only at relatively high concentrations. The estrogenic potency in the immature mouse uterine weight test decreased in the order DES greater than DES-MP much greater than DES-DP. The hormone-dependent MXT mammary tumor of the mouse was inhibited by all three compounds at a dosage of 1.0 mg/kg per week. At a dose of 0.01 mg/kg, DES, DES-MP, and DES-DP stimulated the tumor growth. Thus, for the first time, a biphasic effect on tumor growth was demonstrated in intact mature animals. As the effects of all three compounds were similar in this assay, a cleavage of the phosphate groups is likely. A decrease in estrogenic potency concomitant with a retained antitumor effect of DES-MP and DES-DP compared to DES was not demonstrable in the mature mouse using the MXT assay, only in the uterotrophic test in the immature mouse.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754557     DOI: 10.1007/bf00400747

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  [On the problem of the organ-specific cytostatic effect of diethylstilbestrol diphosphate in prostate carcinoma].

Authors:  G DOERNER; G KNAPPE
Journal:  Klin Wochenschr       Date:  1960-01-15

2.  [Experimental basis of chemotherapy of cancer].

Authors:  H DRUCKREY
Journal:  Dtsch Med Wochenschr       Date:  1952-12-05       Impact factor: 0.628

3.  Estrogen receptor characterization in a transplantable mouse mammary tumor.

Authors:  C Watson; D Medina; J H Clark
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

4.  Influence of estrogens and endocrine ablation on duration of remission produced by ovariectomy or androgen treatment of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors.

Authors:  M N Teller; R J Kaufman; M Bowie; C C Stock
Journal:  Cancer Res       Date:  1969-02       Impact factor: 12.701

5.  Acetoxy-substituted 1,1,2-triphenylbut-1-enes with antiestrogenic and mammary tumor inhibiting properties.

Authors:  M R Schneider; H Ball; H Schönenberger
Journal:  J Med Chem       Date:  1985-12       Impact factor: 7.446

6.  An apparently direct inhibitory effect of oestrogen on the human testis.

Authors:  G Dörner; F Stahl; W Rohde; D Schnorr
Journal:  Endokrinologie       Date:  1975-11

7.  Antiestrogenic effects of LY 117018 in MCF-7 cells.

Authors:  S M Scholl; K K Huff; M E Lippman
Journal:  Endocrinology       Date:  1983-08       Impact factor: 4.736

8.  Receptor status and subsequent sensitivity of subclones of MCF-7 human breast cancer cells surviving exposure to diethylstilbestrol.

Authors:  L J Brandes; M W Hermonat
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

9.  1,1,2-triphenylbut-1-enes: relationship between structure, estradiol receptor affinity, and mammary tumor inhibiting properties.

Authors:  M R Schneider; E von Angerer; H Schönenberger; R T Michel; H P Fortmeyer
Journal:  J Med Chem       Date:  1982-09       Impact factor: 7.446

10.  [On the mechanism of action of stilbestrol diphosphate (honvan) in prostate carcinoma].

Authors:  H DRUCKREY; N BROCK
Journal:  Munch Med Wochenschr       Date:  1960-08-26
View more
  3 in total

1.  Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane.

Authors:  W Schwarz; R W Hartmann; J Engel; M R Schneider; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

2.  [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.

Authors:  T Spruss; S Schertl; M R Schneider; R Gust; K Bauer; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  The tumor-inhibiting effect of diethylstilbestrol and its diphosphate on the Nb-H and Nb-R prostatic carcinomas of the rat.

Authors:  M R Schneider; A Humm; A H Graf
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.